CIQRX Mutual Fund

NAV$16.42

Fund Essentials - as of Mar 31, 2026

Net Assets
$4,465.22
Expense Ratio
0.99%
Dividend Yield (Current)
2.93%
Holdings
338
Inception Date
Dec 8, 2023
Fund Family
Segall Bryaant & Hamill Asset management
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+9.55%
1 Year+26.02%

Asset Allocation

Stocks: 100.00%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
RHHBY:SMRoche Holding A.G.2.29%
NOVN:SMNovartis Ag Ordinary Shares1.85%
ASML:ASAsml Holding Nv1.67%
BBVA:MABanco Bilbao Vizcaya Argentaria S.A. Reg Shs1.60%
GSK:LNGSK plc1.55%
Top 10 Concentration: 15.57%Report Date: Mar 31, 2026
Download all 338 holdings for CIQRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
2.93%
Frequency
Annually

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how CIQRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

CIQRX Mutual Fund Overview

CIQRX Mutual Fund (Segall Bryant & Hamill International Equity Fund Retail Class) is managed by Segall Bryaant & Hamill Asset management with $4,465.22 in net assets. CIQRX expense ratio is 0.99%, holding 338 positions across sectors including Unknown, Health Care, Industrials. Inception date: 2023-12-08.

CIQRX performance shows a YTD return of 9.55%. The 1-year return is 26.02%. CIQRX dividend yield stands at 2.93%, paid annually.

CIQRX top holdings include Roche Holding A.G. (2.3%), Novartis Ag Ordinary Shares (1.9%), Asml Holding Nv (1.7%), Banco Bilbao Vizcaya Argentaria S.A. Reg Shs (1.6%), GSK plc (1.6%). View all CIQRX holdings, sector breakdown, or dividend history.

CIQRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. CIQRX alternatives are available via the screener, along with tax-loss harvesting opportunities.